Devices & Diagnostics
Discovery & Enabling Platform
30+ Speakers, 6 Panel
Discussion, 2 Company Presentation Session, Networking Breaks, and
a Private Cocktail Reception
The Biotech & Life Sciences Global Venture Congress
d-conference is designed to explore the frontiers of biotech &
life sciences, address the venture capital landscape, identify current
trends in innovation, learn scientific discoveries and discover
cutting-edge Biotech and Life Sciences companies.
More than thirty distinguished speakers, six panel
discussions, two innovative company presentation sessions, exclusive
networking breaks, excellent food menu, premium wine/beer selections,
and a private cocktail reception.
Speakers at the conference are world renowned visionaries,
carefully chosen active investors in Biotech and Life Sciences companies,
founders/C-level executives of cutting edge Biotech companies and
renowned thought leaders, movers and shakers of the biotech industry
and analysts. Click here to
see confirmed speakers.
The Innovator Showcase is a presentation by a chosen
few emerging Biotech and Life Sciences companies both private
and public with "imminent funding" potential.
The screening process is extremely rigorous and we will only select
companies that we think are currently fundable.
For example Serenex
two 2005 conference presenters, were able to secure $30M and $17.824M,
Is Presenting: Examples of companies already chosen
to present at the 2006 conference are:
Apply for a company
presentation now !
- 1) $57M funded drug discovery company seeking
$40M Series C
- 2) $30+M funded drug discovery company
ready to go on Phase II and III clinical trials seeking $25M
- 3) $9.2M funded cell therapeutics company
approved for clinical trial seeking $6M
- 4) Clinical Stage Pharmaceutical company,
FDA approved for Phase II trial seeking $15M
- 5) $2.1M funded Targeted drug company seeking
$2.5M for Phase I and Initial Phase II
Exhibitors at the conference will be a chosen few:
companies with cutting edge technologies, Biotech & Life Sciences
products and services, international agencies, high profile Biotech
and Life Science strategic partners and other service providers.
Click here to see details
and apply. You must have at least one executive registered for the
conference to apply for exhibitor space.
Apply for a exhibitor
table now !
already registered for 2006 Conference are from UK, Germany, Israel,
Finland, Scotland, Canada, China and the USA.
where the delegates submit issues for discussion by the panel speakers.
the privacy of our delegates, we don't give out the attendee list.
This d-conference (delegate-driven) will be a congregation
of venture capitalists, corporate investors, strategic investors,
angel investors, institutional investors, investment bankers, commercial
bankers, biotech and life sciences company executives, entrepreneurs,
analysts, thought leaders, scientists, researchers, academicians,
and service providers. Before the conference, all registered delegates
will be requested to submit issues for panel discussion. Past attendees
President & CEO- Serenex, Inc.; CEO-Transave,
Inc.; President/CEO - Digital Bio (South Korea); CEO
- Med Discovery (Switzerland); Director - Exgenis (UK);
CEO - Congenix (Russia); Managing Director- The Carlyle
Group; Professor Of Medicine- Columbia University;
Partner - Phillips Nizer, LLP; Biotech Executive -
Microsoft; President & CEO- BioTrove; President
& COO- Pharmos Corporation; Principal- The Aurora
Funds; Principal- Cannon Design; Principal- Bear
Stearns Health Innoventures; Biotech Entrepreneur (M.D., Ph.D)
- Harvard Medical School; Tech. Advisor & Patent Agent-
Stroock & Stroock & Lavan; Sr. Vice President-
Life Sciences Greenhouse; Sr. Vice President- William
Gallagher Associates; VP of Research & Development/ CSO-
Locus Pharmaceuticals, Inc; VP, Business Development-
Chugai Pharma USA; Vice President- Cytel Inc.; and
I was very impressed
by the GVC event. To put this is perspective, I had just come from
presenting at the DowJones VentureWire conference in San Francisco.
I had anticipated that the DowJones event would be more valuable
to --------, as I had little previous information about GVC. I was
wrong. Overall, the GVC had much better panels and attracted a much
larger number of leading venture capital firms and industry players.
The conference represented two
of the most productive days of my professional career..........
An exciting forum with effective
information transferal. Not to be missed.....
Ms. Maysa Elmasri
Write to - gvcongress "at" saeclub.com
schedule, date, location and speakers are subject to change